PER 3.49% 8.3¢ percheron therapeutics limited

Sarepta gene therapy study missed key target in Duchennes, page-121

  1. 718 Posts.
    lightbulb Created with Sketch. 141
    In terms of any gene therapy treatment regarding DMD, this is an interesting article:
    http://drugbaron.com/why-sareptas-most-recent-failure-in-dmd-was-entirely-predictable/

    And ANP is the only company with a treatment targeting the inflammation side of DMD, with a very encouraging phase 2 trial completed
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.3¢
Change
-0.003(3.49%)
Mkt cap ! $74.82M
Open High Low Value Volume
8.8¢ 8.8¢ 8.2¢ $46.49K 549.5K

Buyers (Bids)

No. Vol. Price($)
1 11758 8.3¢
 

Sellers (Offers)

Price($) Vol. No.
8.4¢ 24250 1
View Market Depth
Last trade - 16.10pm 10/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.